A new drug against Parkinson’s disease could slow or reverse the progression of the disease, according to an experimental study published by the “Nature Medicine Journal” on June 20.
Researchers conducted a placebo-controlled phase 1 trial of an investigational immunotherapy drug called UB-312, including testing the safety and strength of the immune response. The medicine was given for several months using an injection.
“The drug is designed to modify the course of Parkinson’s disease by targeting the underlying cause,” the co-founder of Vaxxinity, the Texas-based pharmaceutical company that worked on the study, told Fox News. , Lou Reese.
“In our phase 1 trial, we showed that UB-312 may be able to stop or even reverse the progression of the disease by successfully targeting aggregated alpha-synuclein [une protéine acide qui s’accumule dans le cerveau]”, he added.
During the trial, 12 out of 13 patients developed antibodies.
Lou Reese called the results a “major step forward in the treatment of Parkinson’s disease.”
Due to these positive results on a small group, the study will continue in phase 2 which will involve a larger group of individuals.
Leiden University Medical Center in the Netherlands, the University of Texas McGovern School of Medicine and the Mayo Clinic in Rochester, Minnesota, also contributed to the study.
